SCHEMBL5030372

SCHEMBL5030372

Cc1nc(Cl)c([N+](=O)[O-])c(NC(C)(C)CN)c1C

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6219208 0.76 POLB (0.39) POLBSMN1; SMN2
SCHEMBL6097284 0.74 POLB (0.39) POLBSMN1; SMN2
SCHEMBL13527456 0.74 POLB (0.42) POLBSMN1; SMN2
SCHEMBL4772531 0.73 POLB (0.41) POLBSMN1; SMN2
SCHEMBL5034513 0.73 POLB (0.34) POLB
SCHEMBL4300514 0.73 POLB (0.40) POLBSMN1; SMN2
SCHEMBL563117 0.72 POLB (0.38) POLB
SCHEMBL4776141 0.72 POLB (0.43) POLBSMN1; SMN2
SCHEMBL2059190 0.72 POLB (0.46) POLBSMN1; SMN2
SCHEMBL14419215 0.71 POLB (0.43) POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 US disclosed
EP-1451187-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-01 EP disclosed
US-6720333-B2 IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE 3M INNOVATIVE PROPERTIES COMPANY 2004-04-13 US disclosed
US-20030162806-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-28 US disclosed
WO-2003050118-A1 AMIDE SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG POLB 2020/4885SMN1; SMN2 3854/4885
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES PAICS, HTR4, PNPO POLB 1618/4885SMN1; SMN2 824/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG POLB 2020/4885SMN1; SMN2 3854/4885
US-20030162806-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG POLB 2020/4885SMN1; SMN2 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.